Stereotaxis, Inc. Common Stock (STXS)
Frequently Asked Questions About Stereotaxis, Inc. Common Stock (STXS)
How can I purchase Stereotaxis stock?
You can purchase Stereotaxis stock (NYSE: STXS) through any brokerage account that allows for trading on the New York Stock Exchange. Investors can buy shares via online platforms, traditional brokerage firms, or through retirement accounts that enable stock purchases. It is recommended to conduct research or consult financial advisors before investing to understand market conditions and the performance of the company.
How does Stereotaxis engage with investors?
Stereotaxis engages with investors through regular financial disclosures, presentations, and participation in investor conferences. The company maintains transparency by providing insights into its business operations, product developments, and financial performance through quarterly earnings reports and updates. Stereotaxis also encourages dialogue with shareholders and analysts to foster engagement and address inquiries related to its strategies and market outlook.
How does Stereotaxis ensure patient safety?
Stereotaxis prioritizes patient safety through the design and development of its robotic systems, which enhance the precision of catheter navigation during procedures. The Niobe system minimizes the risks associated with traditional manual catheter placements, reducing radiation exposure for both patients and healthcare providers. Additionally, the company adheres to strict regulatory standards and conducts thorough testing to ensure that its products meet safety and efficacy criteria.
How does Stereotaxis support healthcare professionals?
Stereotaxis supports healthcare professionals through comprehensive training programs, ongoing education, and technical support related to the use of its robotic platforms. The company provides resources, including workshops, webinars, and on-site training, to ensure that medical personnel can effectively utilize the Niobe system and improve patient care. By fostering collaboration with clinicians, Stereotaxis aims to continuously enhance procedural success.
Is Stereotaxis a publicly traded company?
Yes, Stereotaxis, Inc. is a publicly traded company listed on the New York Stock Exchange (NYSE) under the ticker symbol STXS. The company went public in 2000 and has since been subject to the regulations and reporting requirements of the SEC, providing investors with insights into its financial performance and business operations.
What are some recent developments or innovations from Stereotaxis?
Stereotaxis has continued to innovate its technology through enhancements to the Niobe system and the development of novel applications for robotic navigation in cardiac procedures. Recent efforts have focused on improving software capabilities, integrating advanced imaging technologies, and increasing automation within its systems. These innovations aim to provide physicians with better tools for precision therapy and to expand the system's utility in various clinical settings.
What are Stereotaxis’s future growth plans?
Stereotaxis plans to grow by expanding its operational footprint in both existing and new markets, as well as by diversifying its product offerings within the robotic medical technology space. The company is focusing on strategic partnerships with healthcare providers, exploring additional applications for its technology, and investing in research and development to drive innovation. These efforts aim to solidify Stereotaxis as a leader in the field of electrophysiology and beyond.
What are the key benefits of the Niobe system?
The Niobe system offers several key benefits, including enhanced catheter control, improved procedural precision, and reduced radiation exposure during electrophysiological procedures. The robotic system allows for greater maneuverability and accuracy in navigating complex cardiac anatomies, which can lead to faster procedure times and better outcomes for patients. Its user-friendly interface also aids in the training and efficiency of medical personnel.
What does Stereotaxis, Inc. do?
Stereotaxis, Inc. is a healthcare technology company that specializes in developing innovative robotic systems for the treatment of cardiovascular diseases. Its flagship technology includes the Niobe robotic magnetic navigation system, which allows physicians to perform catheter-based procedures with increased precision and control. The company's mission is to enhance the safety and effectiveness of minimally invasive procedures, improving patient outcomes in the field of electrophysiology.
What financial challenges has Stereotaxis faced?
Like many companies in the healthcare sector, Stereotaxis has faced financial challenges, particularly related to market competition and economic fluctuations. The company has worked to manage operational costs while investing in innovation and growth initiatives. Ensuring sustainable revenue through continued adoption of its technology amidst varying market conditions has been a key focus, and Stereotaxis continues to adapt its strategies to navigate these challenges.
What impact has the COVID-19 pandemic had on Stereotaxis?
The COVID-19 pandemic has had an impact on Stereotaxis, as with many companies in the healthcare sector. Initially, elective procedures, including those requiring the company's technologies, were postponed due to hospital restrictions and patient concerns. However, as healthcare systems adapted and resumed elective surgeries, Stereotaxis experienced a gradual recovery in demand for its products, while also adapting its services to support remote training and consultations.
What is Stereotaxis's commitment to sustainability?
Stereotaxis is committed to sustainability by integrating environmentally-conscious practices into its operations and product development. The company recognizes its responsibility to minimize its environmental impact and actively seeks to implement energy-efficient technologies, reduce material waste, and comply with regulations. Stereotaxis aims to contribute positively to healthcare while maintaining a focus on ecological stewardship.
What is the company’s vision?
Stereotaxis's vision is to transform the treatment of cardiovascular diseases through robotic technologies, enhancing clinician capabilities and improving patient outcomes. The company aims to lead the field of robotic-assisted medical interventions, ultimately contributing to a paradigm shift in healthcare where precision and minimally invasive techniques become the standard for cardiovascular treatments.
What is the Niobe system?
The Niobe system is Stereotaxis's flagship product, a robotic magnetic navigation platform designed to enable physicians to navigate catheters within the heart with enhanced accuracy. The system employs magnetic fields to control the movement of catheters, providing real-time feedback and improving the overall precision of catheter-based interventions. This technology aims to enhance the safety and efficiency of complex procedures, particularly in the treatment of arrhythmias.
What markets does Stereotaxis serve?
Stereotaxis primarily serves the global healthcare market, with a specific focus on the electrophysiology segment of cardiology. The company's technology is utilized in hospitals and medical centers around the world, where it aids in the treatment of heart rhythm disorders. Stereotaxis continues to explore opportunities for expansion into other medical specialties and geographic regions to enhance its market presence.
What types of procedures utilize Stereotaxis's technology?
Stereotaxis's technology is primarily utilized in catheter-based procedures within the field of electrophysiology, particularly for treating cardiac arrhythmias. The Niobe system facilitates complex ablation procedures, allowing physicians to perform targeted therapy on abnormal electrical pathways in the heart. Additionally, the platform can be used for other cardiac interventions, promoting minimally invasive approaches in the treatment of various heart conditions.
When was Stereotaxis, Inc. founded?
Stereotaxis, Inc. was founded in 1990 in St. Louis, Missouri. Since its inception, the company has focused on advancing the field of electrophysiology through the development of its patented robotic navigation technologies. Over the years, Stereotaxis has continued to innovate and expand its product offerings, aiming to improve the standards of care in cardiac procedures.
Where is Stereotaxis headquartered?
Stereotaxis, Inc. is headquartered in St. Louis, Missouri, USA. This location not only serves as the operational hub for the company but also positions it within a vibrant healthcare ecosystem that includes leading hospitals and research institutions. The St. Louis area provides a conducive environment for collaboration and innovation in the medical technology field.
Who are Stereotaxis's competitors?
Stereotaxis faces competition from several companies in the medical device and electrophysiology market. Major competitors include Abbott Laboratories, Medtronic, and Boston Scientific, which provide a variety of cardiac rhythm management devices and technologies. Additionally, there are other firms specializing in robotic assistance and navigation systems, contributing to a competitive landscape in the heart care technology space.
Who are the key executives at Stereotaxis?
Stereotaxis’s leadership team includes seasoned executives with extensive experience in the medical technology field. The company is led by a CEO and a team of senior officers who specialize in various aspects of business operations, including research and development, marketing, and regulatory affairs. Their collective vision and expertise play a vital role in guiding the company towards its goals and ensuring its continued success in the industry.
What is the current price of Stereotaxis, Inc. Common Stock?
The current price of Stereotaxis, Inc. Common Stock is 2.500
When was Stereotaxis, Inc. Common Stock last traded?
The last trade of Stereotaxis, Inc. Common Stock was at 4:10 pm EDT on August 8th, 2025
What is the market capitalization of Stereotaxis, Inc. Common Stock?
The market capitalization of Stereotaxis, Inc. Common Stock is 215.00M
How many shares of Stereotaxis, Inc. Common Stock are outstanding?
Stereotaxis, Inc. Common Stock has 86.00M shares outstanding.